Overview
TB-500 is classified as a thymosin beta-4 fragment peptide. Muscle/tissue repair, flexibility, injury recovery.
Upregulates actin for cell migration and wound healing. Reduces inflammation, encourages new blood vessel growth, and supports stem cell maturation for tissue repair.
Also known as: Thymosin Beta-4 fragment, Tβ4
Category
Thymosin Beta-4 Fragment
Half-Life
2h
Route
SubQ
FDA Status
Not Approved
How Does TB-500 Work?
Upregulates actin for cell migration and wound healing. Reduces inflammation, encourages new blood vessel growth, and supports stem cell maturation for tissue repair.
At the molecular level, TB-500 operates through pathways characteristic of the Thymosin Beta-4 Fragment class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Thymosin Beta-4 wound healing and inflammation
Malinda et al. demonstrate Tβ4 promotes wound healing via enhanced reepithelialization, collagen deposition, angiogenesis, and keratinocyte migration in animal models.
Evidence: preclinical[2]Thymosin β4 activates cardiac progenitor cells for myocardial repair
Smart et al. (Nature) show Tβ4 activates endogenous cardiac progenitor cells, initiating myocardial and vascular regeneration after systemic administration in mice.
Evidence: preclinical[3]Thymosin β4 Phase I safety study in healthy volunteers
Phase I clinical trial demonstrates recombinant Tβ4 is well-tolerated at multiple IV doses in healthy volunteers, with no dose-limiting toxicities or serious adverse events.
Evidence: moderate[4]Thymosin β4 promotes dermal healing in diverse models
Tβ4 accelerates dermal healing in normal, diabetic, steroid-treated, and aged animal models. Phase 2 results show modest efficacy in venous stasis and pressure ulcers.
Evidence: moderate[5]Thymosin β4 reduces cardiac fibrosis and scar formation
Wei et al. show Tβ4 reduces scar formation post-myocardial infarction by inhibiting ROCK1 signaling, promoting neovascularization, and activating cardioprotective pathways.
Evidence: preclinicalSafety Profile
Research-only; well-tolerated in Phase I/II trials. Not FDA-approved for systemic use.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~8% of users | mild |
| Transient fatigue | ~4% of users | mild |
| Headache | ~3% of users | mild |
Sourcing TB-500 for Research
If you're looking to source TB-500 for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
TB-500 — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.